• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Pharmaceutical market grew by 5.3% in 2011

Report: Pharmaceutical market grew by 5.3% in 2011

April 20, 2012
CenterWatch Staff

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

According to new data from Decision Resources' Pharmaview suite, global pharmaceutical sales grew year-over-year by a respectable 5.3% to reach $707 billion, compared with 3.6% year-over-year growth in 2010. The relative weakness of the dollar in 2011 compared to 2010 played a large part in this growth, and many of the major drug companies, such as Pfizer, Abbott, Eli Lilly and Johnson & Johnson all reported positive currency effects in the 2-4% range in 2011.

But, Pharmaview analysis finds that with the industry entering a period of significant patent expiries, and with ongoing economic headwinds and cost-containment efforts by payers worldwide, future growth looks anemic at best. Over the next seven years, the global market is expected to record a compound annual growth rate of just 2.1%, reaching $817 billion in 2018. At the company level, Pfizer retained its spot as the top pharmaceutical company by sales by a considerable margin, with $58 billion in ethical drug sales in 2011. However, with Lipitor now experiencing generic competition, Decision Resources expects Novartis to be the leading company by 2015, and for it to maintain this position throughout the remainder of the forecast period to 2018.

"Unsurprisingly, the major pharmaceutical companies face a host of challenges going forward. Of the current top 10, only GlaxoSmithKline and Johnson & Johnson are expected to show organic growth between 2011 and 2018,” said Pharmaview director Alasdair Milton. “Many of the others, such as AstraZeneca, Merck & Co. and Eli Lilly, are expected to experience a precipitous decline in sales as patent protection around many of their key brands expires.”

Milton added, “The industry remains fragmented, and we believe that there is still room for further consolidation, as the top-line of many companies continues to decline, and shareholders put pressure on management to increase value."

The sales findings are from the most recent release of Decision Resources' Pharmaview, which assesses the commercial aspect of the global pharmaceutical market and provides continually updated analysis of more than 2,900 drugs from more than 280 companies, covering 167 product classes and 14 therapy areas. Pharmaview also provides deep analysis into the world's leading biopharmaceutical companies.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing